The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 )
after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained
on a stable dose of zidovudine ( AZT ). To investigate the optimum dose regimen of U-90152
that gives average trough concentrations > 1 micromolar in combination with standard AZT
therapy, and to examine drug interactions between the two drugs. To establish the MTD of
U-90152 in HIV-1 positive patients on stable AZT therapy. To investigate comparative
pharmacokinetics between HIV-1 positive men and women.